Empowering you with regulatory updates, risk management best practices and audit and inspection tools for safer drugs in Asia
In WHO’s 14th International Conference of Drug Regulatory Authorities (ICDRA), the importance of pharmacovigilance was clearly highlighted in their recommendations:
“Make pharmacovigilance a key topic of the next ICDRA…..reinforce recommendations that the pharmacovigilance system be nested within the healthcare system to address multiple growing safety needs.”
WHO recognizes the importance of pharmacovigilance and values it as much as you do.
Hear directly from WHO at the 3rd Annual Pharmacovigilance Asia 2012, which will gather Heads of Pharmacovigilance, Directors of Drug Safety, Medical Affairs Officers, Medical Safety Managers from Pfizer, Takeda, Bayer, Roche, GSK, Baxter, Abbott, Novartis and country FDAs, amongst others, to discuss issues including*:
- Regulatory updates on pharmacovigilance from WHO’s Uppsala Monitoring Center, European Commission, China, India, Taiwan, South Korea, Malaysia and Brunei
- How you can develop and implement risk management and minimisation plans for improved drug safety
- How you can prepare for audit and inspection: practical steps to get it right
- How you can establish an early signal detection system for improved drug safety
- Best practices in AE reporting for post-marketing surveillance studies
- How you can achieve compliance in various country regulations in Asia while meeting global safety requirements
>> Download the brochure to find out more
>> Find out who’s attending Pharmacovigilance Asia